Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus

References

• Alan, M., et al., 2019. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecological endocrinology: the official journal of the international society of gynecological endocrinology, 35 (3), 220–223.
   PubMed Web of Science ®Google Scholar
• Beutler, L.R., and Knight, Z.A., 2018. A spotlight on appetite. Neuron, 97 (4), 739–741.
   PubMed Web of Science ®Google Scholar
• Chang, C.L., et al., 2019. The serum level of Irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Scientific reports, 9 (1), 6447.
   PubMed Web of Science ®Google Scholar
• Considine, R.V., et al., 1996. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England journal of medicine, 334 (5), 292–295.
   PubMed Web of Science ®Google Scholar
• Donma, M.M., and Donma, O., 2018. Asprosin: possible target in connection with ghrelin and cytokine network expression in the post-burn treatment. Medical hypotheses, 118, 163–168.
   PubMed Web of Science ®Google Scholar
• Duerrschmid, C., et al., 2017. Asprosin is a centrally acting orexigenic hormone. Nature medicine, 23 (12), 1444–1453.
   PubMed Web of Science ®Google Scholar
• Duwaerts, C.C., and Maher, J.J., 2019. Macronutrients and the adipose-liver axis in obesity and fatty liver. Cellular and molecular gastroenterology and hepatology, 7 (4), 749–761.
   PubMed Web of Science ®Google Scholar
• Goto, M., et al., 2006. Ghrelin increases neuropeptide Y and agouti-related peptide gene expression in the arcuate nucleus in rat hypothalamic organotypic cultures. Endocrinology, 147 (11), 5102–5109.
   PubMed Web of Science ®Google Scholar
• Groener, J.B., et al., 2019. Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. PloS One, 14 (9), e0222771.
   PubMed Web of Science ®Google Scholar
• Huh, J.Y., et al., 2012. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism, 61 (12), 1725–1738.
   PubMed Web of Science ®Google Scholar
• Izquierdo, A.G., et al., 2019. Leptin, obesity, and leptin resistance: where are we 25 years later? Nutrients, 11 (11), 2704.
   PubMed Web of Science ®Google Scholar
• Jung, T.W., et al., 2019. Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle. Journal of cellular physiology, 234 (11), 20888–20899.
   PubMed Web of Science ®Google Scholar
• Kajimura, S., 2017. Adipose tissue in 2016: advances in the understanding of adipose tissue biology. Nature reviews endocrinology, 13 (2), 69–70.
   PubMed Web of Science ®Google Scholar
• Kocaman, N., and Kuloğlu, T., 2020. Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model. Tissue & cell, 66, 101397.
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, S., and Kant, R., 2019. An update on metabolic syndrome: metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes and metabolic syndrome, 13 (4), 2409–2417.
   PubMed Web of Science ®Google Scholar
• Li, E., et al., 2019. OLFR734 mediates glucose metabolism as a receptor of asprosin. Cell metabolism, 30 (2), 319.e8–328.e8.
   Web of Science ®Google Scholar
• Li, X., et al., 2018. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators of inflammation, 2018, 1–12.
   Web of Science ®Google Scholar
• Liu, T., et al., 2015. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Clinical science (London, England: 1979), 129 (10), 839–850.
   PubMed Web of Science ®Google Scholar
• Long, W., et al., 2019. Decreased circulating levels of asprosin in obese children. Hormone research in paediatrics, 91 (4), 271–277.
   PubMed Web of Science ®Google Scholar
• Maranta, F., Cianfanelli, L., and Cianflone, D., 2021. Glycaemic control and vascular complications in diabetes mellitus type 2. Advances in experimental medicine and biology, 1307, 129–152.
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete, J.M., et al., 2013. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. The journal of clinical endocrinology and metabolism, 98 (4), E769–E778.
   PubMed Web of Science ®Google Scholar
• Myers, M.G., Cowley, M.A., and Münzberg, H., 2008. Mechanisms of leptin action and leptin resistance. Annual review of physiology, 70, 537–556.
   PubMed Web of Science ®Google Scholar
• Ozata, M., Ozdemir, I.C., and Licinio, J., 1999. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. The journal of clinical endocrinology and metabolism, 84 (10), 3686–3695.
   PubMed Web of Science ®Google Scholar
• Ozcan, S., et al., 2020. The modulatory effects of irisin on asprosin, leptin, glucose levels and lipid profile in healthy and obese male and female rats. Archives of physiology and biochemistry. doi:10.1080/13813455.2020.1727
   Google Scholar
• Pradhan, G., Samson, S.L., and Sun, Y., 2013. Ghrelin: much more than a hunger hormone. Current opinion in clinical nutrition and metabolic care, 16 (6), 619–624.
   PubMed Web of Science ®Google Scholar
• Pulkkinen, L., et al., 2010. Ghrelin in diabetes and metabolic syndrome. International journal of peptides, 2010, 1–11.
   Google Scholar
• Rehman, K., Akash, M., and Alina, Z., 2018. Leptin: a new therapeutic target for treatment of diabetes mellitus. Journal of cellular biochemistry, 119 (7), 5016–5027.
   PubMed Web of Science ®Google Scholar
• Romere, C., et al., 2016. Asprosin, a fasting-induced glucogenic protein hormone. Cell, 165 (3), 566–579.
   PubMed Web of Science ®Google Scholar
• Saeedi, P., et al., 2019. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes research and clinical practice, 157, 107843.
   PubMed Web of Science ®Google Scholar
• Salazar, J., et al., 2020. Is "leptin resistance" another key resistance to manage type 2 diabetes? Current diabetes reviews, 16 (7), 733–749.
   PubMed Web of Science ®Google Scholar
• Schumann, U., et al., 2017. Asprosin, a newly identified fasting-induced hormone is not elevated in obesity and is insensitive to acute exercise: 3592 Board# 39 June 3 800 AM-930 AM. Medicine & science in sports & exercise, 49 (5S), 1023.
   Google Scholar
• Tekin, S., et al., 2017. The effects of intracerebroventricular infusion of irisin on feeding behaviour in rats. Neuroscience letters., 645, 25–32.
   PubMed Web of Science ®Google Scholar
• Ugur, K., and Aydin, S., 2019. Saliva and blood asprosin hormone concentration associated with obesity. International journal of endocrinology, 2019, 2521096.
   PubMed Web of Science ®Google Scholar
• Wang, M., et al., 2019. Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Annals of nutrition and metabolism, 75 (4), 205–212.
   PubMed Web of Science ®Google Scholar
• Wang, Q., et al., 2014. Arcuate AgRP neurons mediate orexigenic and glucoregulatory actions of ghrelin. Molecular metabolism, 3 (1), 64–72.
   PubMed Web of Science ®Google Scholar
• Wang, Y., et al., 2018. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators of inflammation, 2018, 1–7.
   Web of Science ®Google Scholar
• Wiecek, M., et al., 2018. Acute anaerobic exercise affects the secretion of asprosin, irisin, and other cytokines - a comparison between sexes. Frontiers in physiology, 9, 1782.
   PubMed Web of Science ®Google Scholar
• Xiong, X.Q., et al., 2015. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochimica et biophysica acta, 1852 (9), 1867–1875.
   PubMed Web of Science ®Google Scholar
• Zhang, L., et al., 2019. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clinica chimica acta, 489, 183–188.
   PubMed Web of Science ®Google Scholar
• Zhang, X., et al., 2020. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. Journal of diabetes investigation, 11 (2), 349–355.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 1994. Positional cloning of the mouse obese gene and its human homologue. Nature, 372 (6505), 425–432.
   PubMed Web of Science ®Google Scholar